Volume 16, Issue 2 pp. 225-233

Effects of 5-HT3 antagonism on postprandial gastric volume and symptoms in humans

B. Kuo

B. Kuo

Gastroenterology Unit, Massachusetts General Hospital, Boston, MA, USA

Search for more papers by this author
M. Camilleri

M. Camilleri

Enteric Neuroscience Program, Gastroenterology Research Unit, Rochester, MN, USA,

Search for more papers by this author
D. Burton

D. Burton

Enteric Neuroscience Program, Gastroenterology Research Unit, Rochester, MN, USA,

Search for more papers by this author
B. Viramontes

B. Viramontes

Enteric Neuroscience Program, Gastroenterology Research Unit, Rochester, MN, USA,

Search for more papers by this author
S. McKinzie

S. McKinzie

Enteric Neuroscience Program, Gastroenterology Research Unit, Rochester, MN, USA,

Search for more papers by this author
G. Thomforde

G. Thomforde

Enteric Neuroscience Program, Gastroenterology Research Unit, Rochester, MN, USA,

Search for more papers by this author
M. K. O'Connor

M. K. O'Connor

Section of Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN, USA,

Search for more papers by this author
B. H. Brinkmann

B. H. Brinkmann

Section of Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN, USA,

Search for more papers by this author
First published: 18 January 2002
Citations: 50
Dr M. Camilleri, Mayo Clinic, Charlton 7–154, 200 First Street S.W., Rochester, MN 55905, USA. E-mail: [email protected]

Abstract

Background:

Alosetron reduces symptoms of dyspepsia, but the physiological basis for the symptomatic benefit is unclear.

Aim:

To assess 5-HT3 antagonism on postprandial gastric volume and symptoms after ingestion of maximum tolerable volume of a liquid meal.

Methods:

In 36 healthy volunteers, we assessed effects of placebo, 0.5 and 1 mg b.d. alosetron on fasting and postprandial gastric volumes (using single photon emission computed tomography) and symptoms based on 100 mm VAS, 30 min after maximum volume ingested.

Results:

The 5-HT3 antagonist reduced postprandial symptoms (aggregate score: P < 0.05), nausea (P < 0.001), and tended to reduce bloating (P=0.08). Both 0.5 and 1 mg alosetron reduced nausea (P < 0.025); 1 mg alosetron reduced aggregate symptoms (P < 0.05) and bloating (P < 0.05). Effects on pain (P=0.19) and fullness (P=0.14) were not statistically significant. There were no significant effects of the 5-HT3 antagonist on volume of meal tolerated or on SPECT-measured fasting or postprandial gastric volumes.

Conclusion:

5-HT3 antagonism reduces aggregate symptoms, nausea and bloating after a liquid meal without increase in gastric volumes, suggesting a role for 5-HT3 in afferent functions in healthy humans during the postprandial period.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.